The PARP Inhibitor Market is poised to experience trends in genetic testing by personalized medicine

The PARP inhibitor market comprises drugs used in the treatment of certain cancers like breast cancer and ovarian cancer. PARP inhibitors work by blocking an enzyme called poly ADP-ribose polymerase that is involved in DNA repair. Without this enzyme, cancer cells die as they cannot repair their damaged DNA. Some key advantages of PARP inhibitors include better survival rates, fewer side effects compared to chemotherapy, and they can be used for maintenance therapy.

The growing prevalence of cancer worldwide along with increased awareness about personalized medicine and targeted therapies has boosted the PARP inhibitors Market Demand. The Global PARP Inhibitor Market is estimated to be valued at US$ 7.20 Bn in 2025 and is expected to exhibit a CAGR of 8.8% over the forecast period of 2024 to 2031.

Key Takeaways
Key players operating in the PARP inhibitor market are AstraZeneca, GlaxoSmithKline, Merck Co. & Inc, GlaxoSmithKline plc, AbbVie Inc, Clovis Oncology, Medivation. AstraZeneca's Lynparza is one of the leading PARP inhibitors for breast and ovarian cancer indications. GlaxoSmithKline is conducting phase III trials for its PARP inhibitor Zejula in breast and other cancers. The increasing demand for precision medicines to treat cancers more effectively with fewer side effects has boosted the sales of key players.

The growing prevalence of cancer types amendable to PARP inhibitors like breast, ovarian and prostate cancer has augmented the demand. According to WHO, cancer burden is expected to rise by over 50% in the next 20 years. Increasing awareness about PARP inhibitors as a treatment option either alone or in combination with other drugs is propelling the market growth.

The market is witnessing expansion in terms of clinical trials and approvals in new cancer indications. AstraZeneca received FDA approval for Lynparza in prostate and breast cancer in recent years. Companies are also conducting research to develop next-gen PARP inhibitors and combine them with immunotherapies to target multiple cancer types.

Market Key Trends
One of the major trends in the PARP inhibitor market is the increased adoption of genetic testing and screening to identify patients with BRCA mutations and other homologous recombination deficiencies. PARP inhibitors have shown efficacy only in cancers with defects in homologous recombination repair genes like BRCA1 and BRCA2. Identification of such patients through widespread genetic screening helps in improving clinical outcomes by facilitating personalized treatment regimens. This is expected to drive significant growth in the PARP inhibitors market over the coming years.

Porter’s Analysis

Threat of new entrants: High capital investments required to establish new facilities acts as a deterrent for new players to enter the market. Bargaining power of buyers: Large pharmaceutical companies have high bargaining power over small biotech firms developing novel therapies. Bargaining power of suppliers: Established raw material suppliers leverage their expertise and scale of operations to dictate terms. Threat of new substitutes: Ongoing research for more effective cancer treatments can pose a potential threat. Competitive rivalry: Fierce competition between incumbent players to gain higher market share through novel targeted drug development and strategic collaborations.

Geographical Regions

North America accounts for the largest share of the global Parp inhibitor market in terms of value owing to increasing cancer incidence, high healthcare expenditure and advanced healthcare infrastructure.

Asia Pacific region is poised to grow at the fastest rate during the forecast period. Rising geriatric population, improving access to modern therapies and expanding healthcare capabilities are key factors driving growth.

Geographical Regions

The largest share of the global Parp inhibitor market in terms of value is held by North America due to high cancer burden, robust research funding and widespread adoption of premium targeted therapies.

Asia Pacific represents the fastest growing regional market supported by rapidly developing economies, expanding healthcare budgets and robust R&D investments by global pharmaceutical giants to tap into emerging opportunities.

Get this report in Japanese Language-  PARP阻害剤市場

Get this report in Korean language-  PARP 억제제 시장

About Author-

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)